Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Research Abstract |
Amyotrophic lateral sclerosis (ALS)is an adult-onset neurodegenerative disease characterized by selective loss of motor neurons. As compared with vehicle-treated ALS rats, a sequential intrathecal infusion of FGF-2 and EGF followed by hepatocyte growth factor (HGF)resulted in increased neuroblastic cells in the spinal cord of ALS rats, even after the onset of motor neuron disease. It was accompanied by significant suppression of gliogenesis and deposition of chondroitin sulfate. Moreover, angiogenic factors such as FGF-2 and HGF revealed significant neuroprotective effects in ALS rats. Therefore, motor neuron-surrounding microenvironment may be a potential therapeutic target in the future development of regenerative therapy for ALS.
|